For the year ending 2025-12-31, RNA made $18,755K in revenue. -$684,971K in net income. Net profit margin of -3652.20%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Collaboration revenue | 18,755 | 10,897 | ||
| Research and development | 559,159 | 303,593 | ||
| General and administrative | 205,539 | 86,240 | ||
| Total operating expenses | 764,698 | 389,833 | ||
| Loss from operations | -745,943 | -378,936 | ||
| Interest income | 63,255 | 56,882 | ||
| Other expense | -1,943 | -248 | ||
| Total other income | 61,312 | 56,634 | ||
| Net loss | -684,631 | -322,302 | ||
| Net unrealized (losses) gains on marketable securities | -451 | 2,777 | ||
| Foreign currency translation adjustment | 111 | - | ||
| Comprehensive loss | -684,971 | -319,525 | ||
| Basic EPS | -4.97 | -2.89 | ||
| Diluted EPS | -4.97 | -2.89 | ||
| Basic Average Shares | 137,710,000 | 111,582,000 | ||
| Diluted Average Shares | 137,710,000 | 111,582,000 | ||
Avidity Biosciences, Inc. (RNA)
Avidity Biosciences, Inc. (RNA)